Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $1.36 which represents a decrease of $-0.03 or -2.16% from the prior close of $1.39. The stock opened at $1.41 and touched a low ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ...

Citigroup has recently resumed Mersana Therapeutics Inc (MRSN) stock to Buy rating, as announced on November 15, 2024, according to Finviz. Earlier, on March 19, 2024, JP Morgan had raised the stock ...

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product ...

Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...